BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced it will host a conference call and live audio webcast on November 2, 2015, at 8:30 a.m. ET to report third quarter 2015 financial results. To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 67985711. A live audio webcast of the call will also be available on the Investors & Media section of the Company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company's website approximately two hours after the event. About BIND Therapeutics BIND Therapeutics is a clinical-stage nanomedicine company developing Accurins™, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck (known as Merck Sharp & Dohme outside the United States and Canada) and Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals) to develop Accurins based on their proprietary therapeutic payloads and/or targeting ligands. For more information, please visit the Company's website at www.bindtherapeutics.com.